EI
IOVA icon

EFG International’s Iovance Biotherapeutics IOVA Stock Holding History

EFG International’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Hold
40,000
– – ﹤0.01% 637
2026
Q1 		$140K Sell
40,000
-128,000
-76% -$409K ﹤0.01% 614
2025
Q4 		$459K Buy
+168,000
New +$389K 0.01% 485

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

EFG International's IOVA Position: Q2 2026 in Review

EFG International held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 40,000 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #637.

EFG International first reported a position in IOVA in Q4 2025 and has held it in 3 quarters since. The position peaked at $459K in Q4 2025. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • EFG International held 40,000 shares of Iovance Biotherapeutics worth $166K as of Q2 2026.
  • EFG International left its Iovance Biotherapeutics share count unchanged in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of EFG International's portfolio in Q2 2026, its #637 holding.
  • EFG International first reported a position in Iovance Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • EFG International's Iovance Biotherapeutics position peaked at $459K in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.